August 2026 - Tropomyosin Receptor Kinases Inhibitors drug patent information, international generic entry, market access

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No	11,974,998	⤷ Start Trial				⤷ Start Trial
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes	10,813,936	⤷ Start Trial				⤷ Start Trial
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes	11,191,766	⤷ Start Trial				⤷ Start Trial
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No	10,172,861	⤷ Start Trial	Y	Y		⤷ Start Trial
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes	10,172,861	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 1, 2026

TRK inhibitors have a narrow but fast-growing oncology footprint anchored by two approved small molecules, larotrectinib (Vitrakvi) and entrectinib (Rozlytrek), with a third-generation candidate repotrectinib (Augtyro) now in the mix. Patent estates combine compound and composition of matter protection with method-of-treatment and incremental formulation/process claims that shape launch timing, generic risk, and payer access. Litigation and market share are driven by pediatric use, tissue-agnostic biomarker coverage, and cross-resistance in NTRK-mutant cancers.

Which patents protect TRK inhibitors (larotrectinib, entrectinib, repotrectinib) and how broad are they?

Answer (featured snippet): TRK inhibitor patent protection typically spans (1) core kinase inhibitor compound claims, (2) pharmaceutical compositions (solid oral dosage, salts, polymorphs), and (3) method-of-treatment claims tied to NTRK fusions or tumor types. For exclusivity, the practical center of gravity is late-expiring composition/process patents plus pediatric exclusivity and regulatory exclusivity extensions, not only the earliest compound filings.

What is the TRK inhibitor IP structure across the three lead drugs?

TRK inhibitors are built around selective inhibition of TRKA (NTRK1), TRKB (NTRK2), and TRKC (NTRK3). Their patent estates follow standard small-molecule oncology patterns:

Compound patents: broad chemical matter around the inhibitor scaffold and close analogs.
Salt/polymorph/composition patents: coverage for specific crystalline forms, salt selections, and final drug product formulations.
Method-of-use patents: claims for treating tumors with specific NTRK gene fusions, ROS1, ALK co-alterations (notably for entrectinib), and pediatric indications where applicable.
Manufacturing/process patents: controlled crystallization, purification, drying, and particle size control designed to preserve downstream supply and reduce “design-around” freedom.
Regulatory exclusivity leverage: Orange Book-listed patent terms plus pediatric exclusivity windows where they attach.

How many patent families typically cover each TRK inhibitor in the US?

Most TRK inhibitor estates in the US consist of multiple families that overlap in time:

Early families: closest to first approvals and earliest filings.
Late families: formulations, process improvements, and “use” claims that can push enforceable protection into later years.

Patent family counts vary by drug and whether late filings were granted as separate Orange Book-listed entries. For business planning, treat the estate as layered: a first wave that blocks fast generic entry, and a later wave that often blocks “at-risk” launches even if core compound patents expire.

When do TRK inhibitors lose exclusivity in the US (larotrectinib and entrectinib)?

Answer (featured snippet): TRK inhibitor exclusivity loss is driven by the last expiring Orange Book patent(s) plus regulatory exclusivities. In practice, generic launch timing hinges on whether late composition/process patents remain enforceable rather than first compound expirations.

How do Orange Book patent categories change launch timing?

For each drug, generic filing risk depends on the Orange Book entry types:

Pediatric exclusivity (6 months): shifts the “effective” launch date for ANDA filers even if they challenge some listed patents.
Method-of-use patents: can block label-relevant generic entry if the ANDA must carve around claimed indications or if the generic seeks broader labeling.
Composition/polymorph patents: can be harder to design around due to final dosage form requirements (tablet/capsule composition, salt form, and in some cases solid-state characteristics).

What typical timeline features matter for TRK inhibitors?

Key drivers that move exclusivity in the real market:

First BLA/IND-to-approval timeline: determines earliest priority and “tail” from filing.
Label expansion timing: can trigger additional method patents or new Orange Book listings tied to new indications.
Pediatric study outcomes: determine whether pediatric exclusivity is applied.

What Paragraph IV challenges exist for TRK inhibitors and how do settlement agreements affect generic entry?

Answer (featured snippet): Paragraph IV activity for TRK inhibitors is relatively lower visibility than blockbuster oncology, but the strategic pattern is consistent: ANDA filers target one or more listed patents while expecting settlement to delay launch rather than immediate adjudication.

What legal levers matter for generic risk on TRK inhibitors?

Carve-outs vs. litigation: generics can sometimes seek narrow labeling, but TRK indications are biomarker-defined and tissue-agnostic, increasing the likelihood of label overlap.
Orange Book listing completeness: late-added patents can change “at-risk” calculations even after initial ANDA filing strategy.
Injunction leverage: brand holders often negotiate to avoid near-term design-around launches.

How do settlements translate into “real-world” delay?

Settlement terms typically control:

At-risk launch triggers based on patent non-infringement findings or delayed decision schedules.
Design-around constraints that preserve enforceable method/formulation coverage.

How strong is the patent estate for larotrectinib (Vitrakvi) versus entrectinib (Rozlytrek)?

Answer (featured snippet): The stronger estate usually comes from the combination of multiple Orange Book-listed families that extend into later years through formulation/process and method-of-treatment claims tied to NTRK fusion biomarker-driven therapy.

What is the difference in IP exposure between larotrectinib and entrectinib?

Larotrectinib is focused on NTRK fusion biology with a narrower non-NTRK target footprint, so its method-of-use claims are often tightly biomarker-linked.
Entrectinib hits multiple targets (TRK plus ROS1 and ALK), which can expand the addressable label and support broader method-of-use coverage, but also introduces competitive pressure from other multi-kinase inhibitor classes.

Where does patent strength translate into business outcomes?

Formulation/process patents reduce the ability of generics to offer true product equivalence.
Method-of-treatment patents can force label carve-outs or keep the generic from launching at full therapeutic positioning.
Pediatric population is a market-shaping driver because TRK inhibitors have pediatric oncology use cases that can extend value and increase willingness to litigate.

What formulations are protected by TRK inhibitor patents (capsules, tablets, salts, polymorphs)?

Answer (featured snippet): TRK inhibitor formulation patents most often cover specific drug substance salt forms and the final oral dosage form composition, including solid-state characteristics that can be used to block simple “bioequivalent” substitutes.

What formulation elements are usually protected?

Salt selection: specific salts chosen for stability, solubility, and manufacturability.
Polymorph/crystal form: solid-state control that can be critical for dissolution and bioavailability.
Excipients and ratios: composition-level protection for the finished dosage form.
Particle size and milling steps: process-to-formulation linkage can expand enforceable scope.
Manufacturing and crystallization windows: claims that protect how the solid is produced, not only what it is.

How does this affect generic and biosimilar risk?

These are small-molecule oral drugs, so biosimilar risk is not the direct framework. The practical parallel is “generic equivalence risk,” which is dominated by formulation and process claims.
For at-risk generics, the most difficult claims to design around are those that are tied to the marketed dosage form or solid-state characteristics used in development.

How do NTRK fusion biomarkers influence method-of-use patent coverage and label design?

Answer (featured snippet): Method-of-use claims in TRK inhibitor estates are frequently drafted to treatment of tumors defined by NTRK gene fusion status, which directly affects generic label strategy and litigation posture.

Why biomarker-defined claims raise the stakes for generics

TRK indications are tissue-agnostic and driven by genetic test results.
A generic seeking broad labeling must align with the same molecular inclusion criteria that method patents target.
That alignment can increase likelihood of infringement allegations when the ANDA product is tested in a patient population consistent with the claimed method.

How label expansion changes litigation exposure

When sponsors expand indications (age group, tumor type, or combined genomic profiles), they may:

add new Orange Book method-of-use listings tied to the new wording, or
maintain the same method claims that already map to the expanded label.

What patent litigation affects TRK inhibitors right now and what are the outcomes?

Answer (featured snippet): TRK inhibitor patent disputes tend to cluster around generic ANDA filings, Orange Book listing scope, and infringement of method/formulation patents. Outcomes typically shape whether generics launch at full label breadth or under carve-outs.

What to track for ongoing enforcement

Business and litigation monitoring should focus on:

new Orange Book listings after label changes,
district court decisions on claim construction for method and formulation families,
Federal Circuit affirmation or remand that changes enforceability timelines.

What is the Orange Book status of TRK inhibitors (larotrectinib and entrectinib)?

Answer (featured snippet): Orange Book status for each TRK inhibitor reflects multiple listed patents spanning drug substance and drug product categories. Launch planning requires mapping the ANDA challenge strategy to the latest enforceable Orange Book entries and their expiration dates.

What Orange Book fields matter most operationally

Patent number
Expiration date
Patent holder/assignee
Patent type (composition, method, drug substance, drug product)
Regulatory exclusivity codes that signal pediatric or other protections

(Operational note: for TRK inhibitors, the key is not only how many patents are listed, but which ones are “late” and how the method claims track to label wording.)

How does repotrectinib’s TRK inhibitor patent estate change the competitive landscape (Augtyro)?

Answer (featured snippet): Repotrectinib expands competitive pressure through a next-generation TRK inhibition profile, but business impact hinges on whether its late-expiring composition/process and method-of-treatment patents align with current and expected label wording for NTRK fusion-driven disease.

What repotrectinib competition does to market dynamics

New entrants can pressure pricing and formulary decisions even while older drugs retain patent protection.
Payers may shift preferred positioning based on response durability and CNS penetration assumptions tied to next-generation targeting.

Where does the patent estate matter most for repotrectinib?

If repotrectinib adds additional method-of-use coverage for specific resistance mutations or CNS disease settings, it can constrain any competitive substitution more than a compound-only expiration would suggest.
Formulation/process patents can slow generic equivalence.

How does FDA regulatory status shape TRK inhibitor exclusivity and market access?

Answer (featured snippet): FDA status drives exclusivity through approval pathway and pediatric/label expansion outcomes. For TRK inhibitors, tissue-agnostic biomarker use and pediatric uptake intensify the commercial effect of exclusivity and patents.

What regulatory facts matter for exclusivity calculations

Approval dates determine the baseline exclusivity window.
Pediatric study results determine pediatric exclusivity add-ons where applicable.
New indication submissions can expand Orange Book entries.

How does FDA labeling affect patent enforcement leverage?

Method-of-use patents track claim language to label wording. As label expands, method claim relevance can increase even if the underlying molecule stays the same.

What generic entry risks exist for TRK inhibitors and what barriers block launches?

Answer (featured snippet): Generic entry risk is concentrated in late-expiring formulation/process patents and biomarker-defined method claims. Even where core compound patents expire, these later entries can still block full-label generic launches.

Generic scenarios that businesses model

Low-at-risk scenario: only early compound patents challenged or expired; late composition/method patents still enforceable.
High-at-risk scenario: core compound patents expiring soon and late composition/method entries thin or weak; generics pursue at-launch.
Label carve-out scenario: generic is approved with narrowed indication wording to avoid method infringement, which reduces market capture.

Manufacturing and IP barriers

Solid-state control (polymorph, salt) increases development cost and slows “fast-follower” generics.
Process patents add friction by requiring equivalence at the manufacturing level rather than only at the final dosage form.

How do TRK inhibitors compare on commercial exposure and patent-driven revenue protection?

Answer (featured snippet): Revenue protection depends on the interplay between patent enforceability windows and the pace of clinical adoption in pediatric and rare-biomarker oncology. TRK inhibitors have premium pricing dynamics tied to biomarker identification and ongoing evidence generation, which can increase willingness to defend patent exclusivity.

Competitive substitution pressure

Next-generation TRK inhibitors (e.g., repotrectinib) can shift share even when older drugs remain patent-protected.
Clinical positioning for CNS and resistance mutation subsets can become a key driver of brand retention.

Payer and formulary dynamics

Biomarker testing coverage and treatment pathway protocols affect uptake.
Patent-protected exclusivity can align with payer preference structures that favor the currently preferred agent until clinical or price changes warrant switching.

Key Takeaways

TRK inhibitor IP is layered: compound, composition/formulation, and biomarker-defined method patents drive enforceability beyond earliest compound expiration.
Generic entry risk is most affected by late-expiring Orange Book-listed drug product and method-of-treatment patents, plus any pediatric exclusivity.
Repotrectinib changes competitive dynamics through next-generation clinical positioning, but patent scope for method and formulation will determine how quickly competitive substitution can occur.
Commercial exposure is tied to tissue-agnostic NTRK fusion diagnosis workflow, pediatric adoption, and label evolution, all of which increase the practical value of method-of-use claim coverage.

FAQs

1) What patent types most often block generic TRK inhibitor launches?
Composition/formulation drug product patents and biomarker-defined method-of-use patents typically carry the most launch-blocking force.

2) Do TRK inhibitors face biosimilar competition?
No. They are small-molecule therapies, so the competition framework is generics and label carve-outs rather than biosimilars.

3) How do label expansions affect Orange Book listings for TRK inhibitors?
New indications can trigger additional method-of-use listings aligned to the expanded label wording, which can extend effective exclusivity.

4) Can generics rely on label carve-outs to avoid method-of-use infringement for TRK inhibitors?
They can attempt it, but biomarker-defined and tissue-agnostic indications can make carve-outs harder to implement without losing meaningful market capture.

5) What solid-state and process attributes are most relevant for TRK inhibitor generic equivalence?
Salt form, polymorph/crystal form, dissolution-related solid-state properties, and manufacturing crystallization/purification steps are commonly the practical barriers.

References

FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA Drug Approval Packages for larotrectinib (Vitrakvi), entrectinib (Rozlytrek), and repotrectinib (Augtyro). U.S. Food and Drug Administration.
U.S. Patent and Trademark Office (USPTO) Patent Public Search. United States Patent and Trademark Office.